7.49
-0.18 (-2.35%)
| 前收盘价格 | 7.67 |
| 收盘价格 | 7.62 |
| 成交量 | 1,290,022 |
| 平均成交量 (3个月) | 4,001,015 |
| 市值 | 775,836,672 |
| 价格/销量 (P/S) | 14.00 |
| 股市价格/股市净资产 (P/B) | 0.970 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2025 - 11 Aug 2025 |
| 营业利益率 (TTM) | -1,059.86% |
| 稀释每股收益 (EPS TTM) | -5.25 |
| 季度收入增长率 (YOY) | -24.00% |
| 总债务/股东权益 (D/E MRQ) | 24.11% |
| 流动比率 (MRQ) | 5.77 |
| 营业现金流 (OCF TTM) | -348.88 M |
| 杠杆自由现金流 (LFCF TTM) | -133.38 M |
| 资产报酬率 (ROA TTM) | -26.80% |
| 股东权益报酬率 (ROE TTM) | -54.01% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Intellia Therapeutics, Inc. | 混合的 | 看跌 |
AIStockmoo 评分
| 分析师共识 | 4.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.75 |
|
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 5.05% |
| 机构持股比例 | 94.56% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 31 Mar 2025 | 3,702,995 |
| Contrarius Investment Management Ltd | 30 Sep 2024 | 2,047,218 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 68.00 (Chardan Capital, 807.88%) | 购买 |
| 中 | 30.00 (300.53%) | |
| 低 | 10.00 (Wedbush, 33.51%) | 保留 |
| 10.00 (Citigroup, 33.51%) | 保留 | |
| 平均值 | 34.00 (353.94%) | |
| 总计 | 5 购买, 2 保留 | |
| 平均价格@调整类型 | 8.13 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Canaccord Genuity | 03 Jun 2025 | 54.00 (620.96%) | 购买 | 7.69 |
| HC Wainwright & Co. | 29 May 2025 | 30.00 (300.53%) | 购买 | 7.45 |
| 20 May 2025 | 30.00 (300.53%) | 购买 | 9.67 | |
| Wedbush | 19 May 2025 | 10.00 (33.51%) | 保留 | 9.06 |
| Guggenheim | 12 May 2025 | 45.00 (500.80%) | 购买 | 8.55 |
| Chardan Capital | 09 May 2025 | 68.00 (807.88%) | 购买 | 8.12 |
| Citigroup | 09 May 2025 | 10.00 (33.51%) | 保留 | 8.12 |
| Wolfe Research | 21 Apr 2025 | 21.00 (180.37%) | 购买 | 7.92 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合